PBMs typically receive a portion of rebates paid by drug manufacturers, the majority of which are passed back to the payer as an incentive to prefer a drug on a formulary. PBMs may also retain revenue ...
The Maui Derm 2026 meeting featured in-depth discussion surrounding all areas of dermatology. Here, The American Journal of Managed Care ® asked speakers and attendees what their ...
Policy strategist Kristi Martin discusses how the Orphan Drug Act reshapes rare disease treatment and drug-pricing challenges ...
Telomere length and polygenic risk scores (PRS) are linked to idiopathic pulmonary fibrosis (IPF) risk, especially in noncarriers of rare genetic variants. The study identified rare damaging variants ...
Oncodermatology is evolving with nonsurgical approaches and immune checkpoint inhibitors, improving outcomes in aggressive ...
Na’ama Avitzur, MD, is a pulmonologist and a fellow at the University of British Columbia, researching interstitial lung disease and an internal medicine physician. A European Respiratory Journal ...
The Orphan Drug Act revolutionized rare disease treatment, yet rising costs and access issues challenge equitable health care solutions.
The Coalition’s Conversation podcast series is a 3-part discussion on how employers can incorporate glucagon-like peptide-1 (GLP-1) therapies into a sustainable strategy to address obesity and weight ...
Explore the latest advancements in bispecific antibodies for multiple myeloma, focusing on early treatment opportunities and innovative trial designs.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results